Skip to main content
Article
194 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (104 Week) Improvement in Fatigue in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III Randomized Controlled Trials
Rheumatology (2016)
  • Arthur Kavanaugh, University of California, San Diego
  • Dafna D. Gladman, Toronto Western Hospital
  • Christopher J. Edwards, University of Southampton
  • Airi Poder
  • Frédéric Lioté, Paris Diderot University
  • Paul Bird, University of New South Wales
  • Georg Schett, University of Erlangen-Nuremberg
  • Melissa McIlraith, Celgene
  • Lichen Teng, Celgene
  • Philip J. Mease, University of Washington
Publication Date
April 1, 2016
DOI
10.1093/rheumatology/kew145.005
Citation Information
Arthur Kavanaugh, Dafna D. Gladman, Christopher J. Edwards, Airi Poder, et al.. "194 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (104 Week) Improvement in Fatigue in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III Randomized Controlled Trials" Rheumatology Vol. 55 (2016)
Available at: http://works.bepress.com/philip-mease/89/